

Disclosures

Personal Commercial (27)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Research/Research Grants ‡ <i>CardioHealth Alliance</i>	None (\$0)	<i>General Cardiology</i>
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca	Research/Research Grants ‡ <i>EXSCEL</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bayer Corporation US	Consultant Fees/Honoraria	Modest (< \$5,000)	
Bayer Healthcare Pharmaceuticals	Research/Research Grants ‡ <i>CardioHealth Alliance</i>	None (\$0)	<i>General Cardiology</i>
Beam Therapeutics	Research/Research Grants	None (\$0)	<i>Other</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Research/Research Grants ‡ <i>EMPACT-MI; CardioHealth Alliance</i>	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bristol-Myers Squibb Company	Other - <i>BMS acquired Myokardia and consulting via Myokardia</i>	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
CRISPR Therapeutics	Research/Research Grants	None (\$0)	<i>Other</i>
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Eidos	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Eli Lilly and Company	Research/Research Grants ‡ <i>EMPACT-MI; Partnered with Boehringer Ingelheim a</i>	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Intellia	Consultant Fees/Honoraria	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Intercept Pharmaceuticals	Data Safety Monitoring Board	Modest (< \$5,000)	<i>Other</i>
Merck & Co., Inc.	Research/Research Grants	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Novo Nordisk Inc.	Research/Research Grants ‡ <i>CardioHealth Alliance</i>	None (\$0)	<i>General Cardiology</i>
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>
Tikkunlev	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Verve	Research/Research Grants	None (\$0)	<i>Other</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
----------------------------	-----------------------	--------------------	---------------

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Heart Association	Other	None (\$0)	Heart Failure and Cardiomyopathies
National Institutes of Health	Research/Research Grants ‡ NIH Collaboratory, NHLBI Heart Failure Network	None (\$0)	General Cardiology Heart Failure and Cardiomyopathies Other
PCORI	Research/Research Grants ‡ PCORnet	None (\$0)	Other

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/19/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/19/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/19/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/5/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.